Pictet Asset Management Holding SA Makes New $3.15 Million Investment in Erasca, Inc. $ERAS

Pictet Asset Management Holding SA bought a new stake in shares of Erasca, Inc. (NASDAQ:ERAS) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 208,273 shares of the company’s stock, valued at approximately $3,145,000. Pictet Asset Management Holding SA owned 0.07% of Erasca at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ERAS. SG Americas Securities LLC raised its holdings in shares of Erasca by 233.3% in the 4th quarter. SG Americas Securities LLC now owns 48,677 shares of the company’s stock valued at $181,000 after purchasing an additional 34,072 shares in the last quarter. Spruce Street Capital LP acquired a new position in shares of Erasca during the fourth quarter worth $14,469,000. Susquehanna Portfolio Strategies LLC grew its stake in shares of Erasca by 58.4% during the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 59,087 shares of the company’s stock worth $220,000 after purchasing an additional 21,787 shares in the last quarter. Brevan Howard Capital Management LP purchased a new position in Erasca in the second quarter valued at $156,000. Finally, Qtron Investments LLC increased its holdings in Erasca by 219.9% in the third quarter. Qtron Investments LLC now owns 33,593 shares of the company’s stock valued at $73,000 after buying an additional 23,092 shares during the last quarter. Hedge funds and other institutional investors own 67.78% of the company’s stock.

Erasca Stock Performance

Shares of NASDAQ ERAS opened at $18.47 on Friday. Erasca, Inc. has a twelve month low of $1.33 and a twelve month high of $24.28. The stock has a 50 day moving average of $13.42 and a two-hundred day moving average of $12.28. The stock has a market cap of $5.74 billion, a P/E ratio of -19.86 and a beta of 0.66.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.48). As a group, research analysts predict that Erasca, Inc. will post -0.55 earnings per share for the current year.

Key Erasca News

Here are the key news stories impacting Erasca this week:

• Negative Sentiment: Multiple law firms, including Rosen, Schall, Robbins, and Kahn Swick & Foti, are urging investors who bought Erasca shares between January 14, 2025 and April 26, 2026 to seek lead-plaintiff status before the August 10, 2026 deadline, highlighting ongoing securities-fraud litigation risk. Article Title
• Negative Sentiment: The underlying lawsuit focuses on alleged disclosure issues and safety/patent concerns around ERAS-0015, including the patent infringement dispute and reported patient death, which could weigh on investor confidence. Article Title

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ERAS shares. Piper Sandler lifted their price target on Erasca from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Friday, March 13th. Guggenheim boosted their target price on Erasca from $12.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, March 16th. Wolfe Research set a $16.00 price target on Erasca in a report on Thursday, June 4th. Bank of America upgraded shares of Erasca from an “underperform” rating to a “neutral” rating and increased their price target for the company from $9.00 to $16.00 in a research note on Thursday, June 4th. Finally, Stifel Nicolaus raised their price objective on shares of Erasca from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.11.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.